Over the last 18 months, rapid developments have occurred in the dry eye and ocular surface disease space.
After years of limited treatments in these areas, recent approvals include Tyrvaya (varenicline solution, Oyster Point Pharma) and Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals), and patient awareness of dry eye problems is on the rise.
“Patients are actually paying attention, so doctors are looking for it more and more,” Healio/OSN Board Member Kenneth A. Beckman, MD, FACS, said. “We also have more diagnostics and a better ability to